Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment
- 25 November 2009
- journal article
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 18 (5) , 614-617
Abstract
Neurofibromatosis type 1 is one of the most common neurocutaneous autosomal dominant disorders. It is caused by mutations in the neurofibromatosis type 1 (NF1) gene and approximately 30–40% of them affect the correct splicing of NF1 pre-mRNA. In this report, we evaluate the effect of five different drugs, previously found to modify splicing in several genetic disorders, on the splicing of mutated NF1 alleles. For this purpose, cell lines derived from patients bearing 19 different NF1-splicing defects were used. Our results showed that kinetin partially corrects the splicing defect in four of the studied mutations (c.910C>T, c.3113G>A, c.6724C>T and c.6791dupA). Our study is a valuable contribution to the field because it identifies new exon-skipping events that can be reversed by kinetin treatment and provides new information about kinetin splicing modulation. However, owing to the nature of mutations in our patients, kinetin treatment could not be used as a therapeutic agent in these cases.Keywords
This publication has 13 references indexed in Scilit:
- Nature and mRNA effect of 282 differentNF1point mutations: focus on splicing alterationsHuman Mutation, 2008
- Therapeutic potential and mechanism of kinetin as a treatment for the human splicing disease familial dysautonomiaJournal of Molecular Medicine, 2007
- NF1mutation rather than individual genetic variability is the main determinant of theNF1-transcriptional profile of mutations affecting splicingHuman Mutation, 2006
- NF1 mRNA biogenesis: Effect of the genomic milieu in splicing regulation of the NF1 exon 37 regionFEBS Letters, 2006
- Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulationEMBO Reports, 2004
- Rescue of a human mRNA splicing defect by the plant cytokinin kinetinHuman Molecular Genetics, 2003
- EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomiaBiochemical and Biophysical Research Communications, 2003
- Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophyHuman Molecular Genetics, 2003
- Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patientsHuman Molecular Genetics, 2001
- Treatment of spinal muscular atrophy by sodium butyrateProceedings of the National Academy of Sciences, 2001